Werewolf Therapeutics, Inc. (HOWL)

The past six months have seen several events impacting Werewolf Therapeutics, Inc.'s stock price. The company reported Q1 2026 financial results, with a net loss of $13.5M and cash at $46.5M. The MACD for HOWL turned negative, and the Momentum Indicator moved below 0. Werewolf Therapeutics reported Q4 and full-year 2025 financial results and announced the initiation of a strategic review. The company publicly announced its plan to explore strategic alternatives to maximize stockholder value. The Board of Directors approved a 64% workforce reduction to lower operating costs. Werewolf Therapeutics received a notice of non-compliance from Nasdaq regarding its bid price deficiency and audit committee membership requirements. Multiple 10% owners collectively sold 242,890 shares of common stock. The company reported Q3 2025 financial results, emphasizing cash of $65.7M and pipeline milestones. Werewolf Therapeutics received Fast Track Designation from the U.S. Food and Drug Administration for its WTX-124 therapy. Werewolf Therapeutics presented data expanding its PREDATOR platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting.

There is no specific information available regarding demand seasonality for Werewolf Therapeutics, Inc.'s products and services. Demand for their products, once approved, would likely be driven by medical need and treatment efficacy rather than seasonal patterns.

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics designed to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company operates within the Biotechnology & Medical Research industry. Werewolf Therapeutics leverages its proprietary PREDATOR platform to engineer conditionally activated INDUKINE and INDUCER molecules, designed to remain inactive in peripheral tissues and selectively activate within the tumor microenvironment. Major product candidates include WTX-124, WTX-330, JZP898, WTX-1011, WTX-2022, WTX-712, WTX-518, and WTX-921.

Werewolf Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States, and was incorporated in 2017. Another source indicates its headquarters in Cambridge, MA.

Werewolf Therapeutics aims to develop novel, tumor-activated immunotherapies for cancer. The company has actively engaged in scientific discourse, presenting data at conferences and launching the "Full Moon Moment" campaign. However, the company has also faced challenges, such as receiving a notice of non-compliance from Nasdaq and announcing strategic alternatives and a significant workforce reduction, which could impact its reputation.

Werewolf Therapeutics, Inc. has a mixed ownership structure, with institutional, insider, and retail investors. As of May 4, 2026, 56 institutional owners and shareholders hold a total of 19,110,562 shares, approximately 64.84% of the stock. Major institutional owners include Ra Capital Management, L.p., Mpm Asset Management Llc, and Vanguard Group Inc. Insiders own approximately 40.90% of the company's stock. Major individual and insider owners include MPM BioVentures 2014 LP, Ansbert Gadicke, and Peter Kolchinsky.